Infusion-related reactions of Ocrelizumab

The Prevalence and Associated Factors of Infusion-related Reactions of Ocrelizumab (Xacrel®) with Adjusted Premedications in Multiple Sclerosis Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090429001859N10

Enrollment

154

Registered

2023-07-08

Start date

2023-07-11

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Premedication of patients before Ocrelizumab injection will include 8 mg of dexamethasone in 100 cc of normal saline. The purpose of the intervention is to reduce r

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with multiple sclerosis who received Ocrelizumab prescribed by a MS fellowship Received at least 2 doses of the medication Sign the written informed consent

Exclusion criteria

Exclusion criteria: History of other severe underlying disease History of anaphylaxis or any severe allergic reaction to previous medications

Design outcomes

Primary

Measure	Time frame
Infusion-related reactions of Ocrelizumab. Timepoint: Recording infusion-related reactions of Ocrelizumab during infusion until one hour after injection (that patient is still in the hospital) and 24 hours after injection. Method of measurement: Questionnaire of infusion-related reactions of Ocrelizumab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Ali Sahraian

Tehran University of Medical Sciences

msahrai@sina.tums.ac.ir+98 21 6634 8571

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026